Neonc Technologies CFO Garnett sells $16,809 stock

CFO of NEONC TECHNOLOGIES HOLDINGS, INC., Keithly Garnett, sold 5,000 shares of the company's common stock on September 15, 2026. The shares were traded at $3.3618 per share, resulting in a total value of approximately $16,809. The company's stock price was near its 52-week low of $2.96, which represented a significant drop of about 75% from its 52-week high of $12.99.

Analysts from InvestingPro suggest that the stock is currently undervalued, with a market cap of $82.28 million. The transaction was carried out in accordance with a Rule 10b5-1 trading plan that Garnett established on June 16, 2026. After this sale, Garnett personally held 237,357 shares, including those owned by family members, though he disclaimed beneficial ownership in all but his own pecuniary interest.

Indirectly, through his role in The Hilkiah Group LLC, Garnett beneficially owns 44,053 shares, which represent a 4.3% stake in HCWG LLC, the entity that holds these shares. NeOnc Technologies recently revealed positive Phase 2a study results for its intranasal NEO100 treatment in patients with recurrent IDH1-mutant high-grade glioma.

The study met its primary goal, with a six-month progression-free survival rate of 48.9% and a median overall survival of 26.09 months. Roth/MKM upgraded their rating on NeOnc Technologies to a buy, setting a price target of $20.00 based on a discounted cash flow model projecting substantial future operating income. The company also received FDA feedback on manufacturing requirements for NEO212, which was deemed sufficient to allow them to cancel a planned Type B End-of-Phase 1 meeting.